Figure 4

Figure 4. Expression profiles of zebrafish pgfa, pgfb, fgf2, tgfb1, igf2a and igf2b genes. The graphs show data of the mRNA expression of (a) pgfa, (b) pgfb, (c) fgf2, (d) tgfb1a, (e) igf2a and (f) igf2b from pooled 72-h post-fertilization (hpf) wild-type zebrafish larvae (n = 30) in six experimental groups: (1) control; (2) exposed to 5 mM CoCl₂; (3) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L bromocriptine; (4) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L cabergoline; (5) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L pergolide; and (6) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L bevacizumab. Each group was covered by samples analyzed in triplicate in three separate experiments. Data in the figure represent the average of the three individual experiments. Gene expression values were normalized to housekeeping gene ef1-α; 5 mM CoCl₂ exposure resulted in significant downregulation of the expression of all the above-mentioned genes in comparison to the control group (a–f). Co-treatment with 2.5 µM/L bromocriptine, 2.5 µM/L cabergoline, 2.5 µM/L pergolide and 2.5 µM/L bevacizumab resulted in a statistically significant increase of the expression of previously up downregulated pgfa and pgfb (a,b). Co-treatment with dopaminergic agonists has varied influence on genes encoding the chosen growth factors (see detailed description in the text) (c–g). (One-way ANOVA, GraphPad Prism 5, *** p < 0.001; ** p < 0.01; * p < 0.05; ns: not statistically significant differences (p > 0.05)).